Open AccessZoledronic acid, an aminobisphosphonate, prolongs survival of skin allografts
Author(s) -
Chia-Yuan Liu,
PoSheng Yang,
ShihPing Cheng,
YuChuen Huang,
Jie-Jen Lee,
Chun-Chuan Ko,
Hui-Ru Shieh,
Yu-Jen Chen
Publication year - 2012
Publication title -
clinical and investigative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.391
H-Index - 47
eISSN - 1488-2353
pISSN - 0147-958X
DOI - 10.25011/cim.v35i4.17144
Subject(s) - zoledronic acid , medicine , creatinine , bisphosphonate , toxicity , spleen , lymph , histopathology , gastroenterology , urology , immunology , pathology , osteoporosis
Purpose: Zoledronic acid (ZOL), an effective nitrogen-containing bisphosphonate used to prevent excessive bone loss in clinical practice, has been shown to affect the development of dendritic cells by redirecting differentiation toward a state of atypical maturation. The study was aimed to examine whether ZOL can reduce acute rejection of skin allografts.Methods: A skin transplantation model using C57BL/6 to BALB/c mice was used. ZOL was injected intraperitoneally into transplant recipients post-surgically. Graft survival, body weight, leukocyte count, hepatic and renal functions were assessed.Results: ZOL treatment significantly prolonged skin allograft survival in mice. In terms of toxicity, there were no significant differences in body weight, leukocyte count, plasma alanine aminotransferase or creatinine levels between the ZOL-treated and control groups. Histopathology showed that the loss of skin integrity seen in control group was prevented by ZOL treatment. In draining lymph nodes and spleen, the number and clustering extent of mononuclear cells were markedly declined by ZOL treatment. The plasma IL-6 levels were reduced by treatment of ZOL.Conclusion: ZOL can prolong skin allograft survival without major toxicity.